• If you are looking at Bausch Health Companies and wondering whether the current share price reflects its underlying value, you are not alone.
• The stock last closed at US$6.04, with returns of 1.9% over the past week and 5.6% over the past month, against year to date and 1 year returns of 16.2% and 21.0% declines, and a 34.7% and 81.1% decline over 3 and 5 years respectively.
• These moves have kept valuation in focus for many investors, especially as headlines continue to frame Bausch Health Companies as a complex turnaround story with an eye on balance sheet repair and portfolio focus. This broader context helps explain why the share price can react strongly to news about its debt position, product portfolio, or any large corporate actions.
• Based on Simply Wall St's framework, Bausch Health Companies has a valuation score of 4/6. This means it screens as undervalued on four of six checks. Below we look at what different valuation methods say about that, before finishing with a more rounded way to think about the company's value.

Approach 1: Bausch Health Companies Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a company could generate in the future and discounts those cash flows back to today, giving an estimate of what the business might be worth right now.

For Bausch Health Companies, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model. The latest twelve month free cash flow is about $1.03b. Analyst inputs and extrapolated estimates point to projected free cash flow of about $2.36b in 2030, with a path of projected cash flows between 2026 and 2035 that are discounted back to today.

On this basis, the model arrives at an estimated intrinsic value of about $64.87 per share. Relative to the recent share price of US$6.04, this implies the stock screens as around 90.7% undervalued using this DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bausch Health Companies is undervalued by 90.7%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: Bausch Health Companies Price vs Earnings

For a company that is generating earnings, the P/E ratio is a straightforward way to see how much investors are paying for each dollar of profit. It links the share price directly to earnings, which is often more informative than looking at revenue or assets alone.

What counts as a fair P/E depends on how the market views the company’s growth potential and risk. Higher expected growth and lower perceived risk usually support a higher P/E, while lower growth expectations or higher risk tend to mean a lower P/E looks more reasonable.

Bausch Health Companies currently trades on a P/E of 14.26x, compared to the Pharmaceuticals industry average of 19.89x and a peer group average of 12.81x. Simply Wall St’s Fair Ratio for Bausch Health Companies is 22.11x. This Fair Ratio is a proprietary estimate of what the P/E might be given factors such as the company’s earnings profile, industry, profit margins, market cap and specific risks. Because it is tailored to the company, it can offer a more targeted reference point than broad industry or peer comparisons alone. On this basis, the current P/E of 14.26x sits below the Fair Ratio of 22.11x, which indicates that the shares appear undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Bausch Health Companies Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story for a company, tying together your assumptions for future revenue, earnings and margins with a fair value that you can compare to the current share price.

On Simply Wall St, Narratives sit in the Community page and give you an easy way to connect the story you believe about Bausch Health Companies to a set of numbers, so you can see in one place how your view on things like product opportunities, debt and pricing risk translates into a forecast and an estimated fair value.

Narratives update automatically when new earnings, news or guidance is added, and they help you decide whether Bausch Health Companies looks attractively priced or not by setting your Fair Value next to the live market price rather than relying only on a single static model.

For example, one Bausch Health Companies Narrative currently anchors on a fair value of US$5.00 while another uses US$10.00, showing how different investors can look at the same business, plug in different views on revenue trends, profit margins and future P/E, and reach very different but clearly framed conclusions.

For Bausch Health Companies, however, we will make it really easy for you with previews of two leading Bausch Health Companies Narratives:

Fair value in this Narrative: US$7.86 per share

Implied discount to this fair value at US$6.04: about 23.2%

Modeled revenue trend: 2.0% annual decline

• Focuses on affordable medicines in areas like gastroenterology, hepatology and branded generics, with contributions from regions such as EMEA, Canada and Latin America to support a diversified revenue base.
• Assumes gradual improvement in profit margins and earnings out to 2028, with analysts using an 11.5% discount rate and a future P/E of 11.3x to reach a fair value of US$7.86.
• Flags key risks including potential Xifaxan price cuts under U.S. Medicare negotiations, high gross debt of about US$16.1b, regulatory pricing pressure and execution risk around acquisitions and late stage assets.

Fair value in this Narrative: US$5.00 per share

Implied premium to this fair value at US$6.04: about 20.8%

Modeled revenue trend: 1.2% annual growth

• Emphasizes pressure from forced drug price negotiations, generic and biosimilar competition and broader pricing headwinds that could compress margins across key franchises like Xifaxan.
• Builds in concerns that a US$16.1b debt load and an aging portfolio may limit the payoff from acquisitions and pipeline projects, even with earnings and margins assumed to improve by 2028.
• Uses a lower future P/E of 7.1x and an 11.5% discount rate to arrive at a US$5.00 fair value, with the current US$6.04 share price sitting above this bearish anchor.

Do you think there's more to the story for Bausch Health Companies? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.